Can NacBI-RADS Redefine Breast Cancer Therapy Response?
Accurate assessment of treatment response during neoadjuvant chemotherapy guides surgical planning in oncology. However, conventional size-based criteria often underestimate biological tumor regression. Consequently, researchers designed a standardized multiparametric magnetic resonance imaging framework. The implementation of NacBI-RADS in breast cancer care addresses this critical diagnostic gap. This structured reporting system captures dynamic cellular and vascular alterations during systemic therapy.
Understanding the Four Pillars of NacBI-RADS
The novel NacBI-RADS system synthesizes four multiparametric MRI variables into an intuitive scoring tool. First, radiologists evaluate peritumoral edema on T2-weighted sequences to capture local inflammatory changes. Second, the framework quantifies apparent diffusion coefficient changes to monitor cellular breakdown. Third, clinicians measure post-contrast tumor dimensions using dynamic contrast-enhanced T1-weighted sequences. Finally, readers assess regional nodal involvement using established Node-RADS criteria. Therefore, the composite category offers a holistic view of the tumor microenvironment.
Diagnostic Accuracy and Inter-Reader Reproducibility
In a validation cohort of 68 patients, the scoring system demonstrated outstanding diagnostic capability. Residual malignancy occurred in 43 patients, whereas 25 patients achieved a pathological complete response. Importantly, receiver operating characteristic analysis yielded an area under the curve between 0.942 and 0.960 across readers. Furthermore, the scoring system exhibited exceptional inter-reader agreement, with kappa values ranging from 0.931 to 0.953. Most patients mapped into NacBI-RADS categories 1 and 2, which strongly correlated with complete or near-complete pathological response. Conversely, higher scoring categories accurately identified significant residual disease.
Implementing NacBI-RADS in breast cancer practice
For surgical oncologists, NacBI-RADS in breast cancer care provides actionable clarity. Specifically, identifying complete responders allows surgeons to consider breast-conserving surgery or de-escalated axillary procedures safely. Meanwhile, identifying poor responders early can prevent futile interventions and enable prompt second-line systemic therapy. Standardized reporting eliminates subjective discrepancies across radiology departments. As a result, multidisciplinary tumor boards can formulate precise operative strategies with enhanced confidence.
Frequently Asked Questions
Q1: What parameters form the NacBI-RADS scoring system?
The scoring system incorporates peritumoral edema on T2-weighted MRI, apparent diffusion coefficient changes, post-contrast tumor size, and Node-RADS nodal status.
Q2: How does NacBI-RADS influence surgical decision-making?
It reliably predicts pathological complete response, which helps oncologists safely de-escalate surgery or switch ineffective chemotherapy regimens.
Q3: How reproducible is NacBI-RADS among different radiologists?
The system demonstrates excellent inter-reader reproducibility, achieving kappa values between 0.931 and 0.953 among independent radiologists.
References
- Cicciarelli F et al. Multiparametric MRI to predict response to neoadjuvant chemotherapy in breast cancer: Are we ready for NacBI-RADS? Eur Radiol. 2026 Nov 10. doi: 10.1007/s00330-026-12805-z. PMID: 43007412.
- Marinovich ML et al. Breast MRI for Evaluation of Response to Neoadjuvant Therapy. RadioGraphics. 2021;41(7):E160-E162.
- Hottat NA et al. Value of diffusion-weighted MRI in predicting early response to neoadjuvant chemotherapy of breast cancer: comparison between ROI-ADC and whole-lesion-ADC measurements. Eur Radiol. 2022;32(6):4067-4078.
